Insulin aspart faster-acting - Novo Nordisk
Alternative Names: Faster aspart; FIAsp; Fiasp; NN-1218Latest Information Update: 28 May 2024
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in Germany (SC, Injection)
- 28 May 2024 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in Hong Kong (SC, Injection)
- 28 May 2024 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Germany (SC, Injection)